Table 2 Association between CILP2 expression level and clinicopathological parameters in CRC patients
Clinicopathological parameters | Expression of CILP2 mRNA in TGCA | Expression of CILP2 protein in TMA cohort | ||||
|---|---|---|---|---|---|---|
High (n = 310) | Low (n = 311) | P value | High (n = 39) | Low (n = 25) | P value | |
Age (years) | Â | Â | 0.059 | Â | Â | 0.37 |
 ≤ 68 (n = 331) | 177 (53.47%) | 154 (46.53%) |  | 20 (66.67%) | 10 (33.33%) |  |
 > 68 (n = 290) | 133 (45.86%) | 157 (54.14%) |  | 19 (55.88%) | 15 (44.12%) |  |
Gender | Â | Â | 0.400 | Â | Â | 0.8 |
 Male (n = 331) | 160 (48.34%) | 171 (51.66%) |  | 22 (62.86%) | 13 (37.14%) |  |
 Female (n = 290) | 150 (51.72%) | 140 (48.28%) |  | 17 (58.62%) | 12 (41.38%) |  |
Pathological T stagea | Â | Â | 0.001 | Â | Â | 0.022 |
 T1/2 (n = 126) | 46 (36.51%) | 80 (63.49%) |  | 13 (44.83%) | 16 (55.17%) |  |
 T3/4 (n = 493) | 263 (53.35%) | 230 (46.65%) |  | 26 (74.29%) | 9 (25.71%) |  |
N stagea | Â | Â | 0.005 | Â | Â | 0.2 |
 N0 (n = 352) | 158 (44.89%) | 194 (55.11%) |  | 16 (51.61%) | 15 (48.39%) |  |
 N1/2/3 (n = 265) | 149 (56.23%) | 116 (43.77%) |  | 23 (69.70%) | 10 (30.30%) |  |
M stagea | Â | Â | 0.048 | Â | Â | 0.074 |
 M0 (n = 458) | 223 (48.69%) | 235 (51.31%) |  | 30 (55.56%) | 24 (44.44%) |  |
 M1 (n = 88) | 53 (60.23%) | 35 (39.77%) |  | 9 (90.00%) | 1 (10.00%) |  |
Clinical stagea | Â | Â | < 0.001 | Â | Â | 0.03 |
 Stage I (n = 105) | 36 (34.29%) | 69 (65.71%) |  | 5 (35.71%) | 9 (64.29%) |  |
 Stage II (n = 229) | 113 (49.35%) | 116 (50.65%) |  | 8 (50.00%) | 8 (50.00%) |  |
 Stage III (n = 179) | 97 (54.19%) | 82 (45.81%) |  | 17 (70.83%) | 7 (29.17%) |  |
 Stage IV (n = 90) | 54 (60.00%) | 36 (40.00%) |  | 9 (90.00%) | 1 (10.00%) |  |